off-label use of glp-1 agonists for obesity in 2016 Emerging Role Obesity: A Comprehensive Review of Randomised Controlled Trials Huge spike in the use
Description
(2020, March 10)
Enhanced GIP secretion in obesity is associated with biochemical alteration and miRNA contribution to the development of liver steatosis
T.SunH.ChanA
Utilization management tools are intended to balance cost control and access but may still pose barriers for people with a medical necessity to take these drugs
Figure 1 summarizes the key effects of GLP-1 on target tissues
Tailored for humans, it achieved the FDAs approval list in 2017 for the treatment of type 2 diabetes
